February 27, 2017 09:21 AM ESTUpdated 10:32 AM

Pieris inks a licensing deal for Japan; Kindler joins Pharma Two B board with $30M raise; Ampio plots new pain study

Shehla Shakoor

Managing Director

→ Boston-based Pieris $PIRS has optioned a licensing pact giving ASKA Pharmaceutical development and commercialization rights for the anemia drug PRS-080 in Japan and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pieris inks a licensing deal for Japan; Kindler joins Pharma Two B board with $30M raise; Ampio plots new pain study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Pieris inks a li­cens­ing deal for Japan; Kindler joins Phar­ma Two B board with $30M raise; Am­pio plots new pain study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Pieris inks a licensing deal for Japan; Kindler joins Pharma Two B board with $30M raise; Ampio plots new pain study

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?